TITAN PHARMACEUTICALS INC: auditor change — Titan Pharmaceuticals receives Nasdaq delisting notice for late Q3 filing; auditor Withum resigns

TITAN PHARMACEUTICALS INC

Received Nasdaq 5250 Notice on Nov 22 for failure to file Q3 10-Q; compliance plan due Jan 21, 2025, exception to May 19, 2025.
Received Nasdaq 5605 Notice on Nov 25 for audit committee non-compliance due to Brynner Chiam's acting PEO/PFO role; cure until next annual meeting or Nov 6, 2025.
Auditor WithumSmith+Brown resigned effective Nov 22, 2024, citing former CEO's resignation; no disagreements or reportable events.
Company working to file Q3 10-Q and plans to appoint an additional independent director.

item 3.01 item 4.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

WithumSmith+Brown, PC resigned as auditor of TITAN PHARMACEUTICALS INC.

Action: resignation
Auditor: WithumSmith+Brown, PC

Exact text from the filing

On November 22, 2024, WithumSmith+Brown, PC ("Withum") resigned as the Company's independent registered public accounting firm, effective immediately.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001829126-24-007864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.